文献速递胸部肿瘤

帕博利珠单抗对比化疗一线治疗PD-L1肿瘤比例评分≥1%的非小细胞肺癌患者的五年结局:KEYNOTE-042研究

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
PubMed 文献 · J Clin Oncol · 2022-10-28

帕博利珠单抗在各PD-L1 TPS组均显示总生存获益,5年OS率分别为21.9%(TPS≥50%)、19.4%(TPS≥20%)、16.6%(TPS≥1%),未发现新毒性。

要点

  • 帕博利珠单抗对比化疗的OS HR:TPS≥50%为0.68(95%CI 0.57-0.81),TPS≥20%为0.75(0.64-0.87),TPS≥1%为0.79(0.70-0.89)。
  • 帕博利珠单抗组5年OS率:TPS≥50%为21.9%,TPS≥20%为19.4%,TPS≥1%为16.6%。
  • 完成35周期帕博利珠单抗的102例患者客观缓解率为84.3%,接受第二疗程帕博利珠单抗的33例患者为15.2%。

核心结论

  • 在无EGFR/ALK突变、PD-L1阳性的局部晚期/转移性NSCLC患者中,一线帕博利珠单抗单药治疗在5年随访后对比化疗持续显示持久的临床获益,仍为标准治疗。

研究设计与样本

  • III期KEYNOTE-042研究(ClinicalTrials.gov标识符:NCT02220894),纳入无EGFR/ALK突变、PD-L1 TPS≥1%的局部晚期/转移性NSCLC患者。
  • 患者随机接受帕博利珠单抗200 mg每3周一次共35周期,或化疗(卡铂+紫杉醇或培美曲塞)4-6周期,可选培美曲塞维持治疗。
  • 主要终点为PD-L1 TPS≥50%、≥20%和≥1%组的总生存期(OS)。
  • 完成35周期帕博利珠单抗且疾病稳定或更好的患者可在进展后开始第二疗程帕博利珠单抗。

主要发现

  • OS结果 favoring 帕博利珠单抗(对比化疗) regardless of PD-L1 TPS:TPS≥50%组HR 0.68(95%CI 0.57-0.81);TPS≥20%组HR 0.75(95%CI 0.64-0.87);TPS≥1%组HR 0.79(95%CI 0.70-0.89)。
  • 帕博利珠单抗组估计5年OS率:TPS≥50%组为21.9%,TPS≥20%组为19.4%,TPS≥1%组为16.6%。
  • 未发现新的毒性。
  • 完成35周期帕博利珠单抗的102例患者中客观缓解率为84.3%;接受第二疗程帕博利珠单抗的33例患者中客观缓解率为15.2%。

关键数值与推荐

  • PD-L1 TPS≥50%组:帕博利珠单抗对比化疗的OS HR为0.68(95%CI 0.57-0.81)。
  • PD-L1 TPS≥20%组:帕博利珠单抗对比化疗的OS HR为0.75(95%CI 0.64-0.87)。
  • PD-L1 TPS≥1%组:帕博利珠单抗对比化疗的OS HR为0.79(95%CI 0.70-0.89)。
  • 帕博利珠单抗组5年OS率:TPS≥50%组21.9%,TPS≥20%组19.4%,TPS≥1%组16.6%。

临床怎么用

  • 一线帕博利珠单抗单药治疗在PD-L1阳性、无EGFR/ALK突变的局部晚期/转移性NSCLC中,5年随访后对比化疗持续显示持久的临床获益,仍为标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 5-year results from the phase III KEYNOTE-042 study (ClinicalTrials.gov identifier: NCT02220894). Eligible patients with locally advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations and with programmed death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 1% received pembrolizumab 200 mg once every 3 weeks for 35 cycles or chemotherapy (carboplatin + paclitaxel or pemetrexed) for 4-6 cycles with optional maintenance pemetrexed. Primary end points were overall survival (OS) in PD-L1 TPS ≥ 50%, ≥ 20%, and ≥ 1% groups. Patients who completed 35 cycles of pembrolizumab with ≥ stable disease could begin second-course pembrolizumab upon progression. One thousand two hundred seventy-four patients were randomly assigned (pembrolizumab, n = 637; chemotherapy, n = 637). Median follow-up time was 61.1 (range, 50.0-76.3) months. OS outcomes favored pembrolizumab (v chemotherapy) regardless of PD-L1 TPS (hazard ratio [95% CI] for TPS ≥ 50%, 0.68 [0.57 to 0.81]; TPS ≥ 20%, 0.75 [0.64 to 0.87]; TPS ≥ 1%, 0.79 [0.70 to 0.89]), with estimated 5-year OS rates with pembrolizumab of 21.9%, 19.4%, and 16.6%, respectively. No new toxicities were identified. Objective response rate was 84.3% among 102 patients who completed 35 cycles of pembrolizumab and 15.2% among 33 patients who received second-course pembrolizumab. First-line pembrolizumab monotherapy continued to show durable clinical benefit versus chemotherapy after 5 years of follow-up in PD-L1-positive, locally advanced/metastatic NSCLC without EGFR/ALK alterations and remains a standard of care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. de Castro G, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol. 2022. PMID: 36306479. doi:10.1200/JCO.21.02885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。